A press release from the drug maker said it is the first prequalification for a generic version of Pfizer#39;s COVID-19 oral anti-viral drug #39;Paxlovid,#39; which the WHO called, the best therapeutic choice for high-risk patients to date.
A press release from the drug maker said it is the first prequalification for a generic version of Pfizer#39;s COVID-19 oral anti-viral drug #39;Paxlovid,#39; which the WHO called, the best therapeutic choice for high-risk patients to date.
English 
हिन्दी